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a b s t r a c t 
Spinal cord glioblastoma is a rare disease, with an aggressive course and a poor progno- 
sis. We describe magnetic resonance imaging (MRI) findings, in 3 adult cases of biopsy- 
confirmed glioblastoma. 
Conventional MRI findings were unclear with regard to the differential diagnosis be- 
tween this rare tumor and other more common spinal cord lesions, including less aggressive 
tumors such as ependymoma or pilocytic astrocytoma, abscesses or tumefactive demyeli- 
nating lesions. After reasonable exclusion of infectious/inflammatory conditions, a final di- 
agnosis of glioblastoma was established based on histopathological analysis. The cases re- 
ported reflect the difficulty of early radiological diagnosis of spinal cord glioblastoma, and 
indicate the need to perform a biopsy once inflammatory-infectious conditions are excluded 
with appropriate laboratory tests. 
© 2020 Published by Elsevier Inc. on behalf of University of Washington. 
This is an open access article under the CC BY-NC-ND license 











Although glioblastoma (GB) is the most common primary ma-
lignant tumor of the central nervous system (CNS), their loca-
tion in the spinal cord is extremely rare with less than 200✩ Declaration of competing interest: None. 
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counts for approximately 7.5% of all intramedullary gliomas
and 1.5% of all spinal cord tumors [1] . It has a highly aggressive
course with a very poor prognosis due to its infiltrative growth
and the impossibility of complete surgical resection. Median
survival rate is approximately 14 months, even in the settingashington. This is an open access article under the CC 
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Fig. 1 – Spinal cord MRI from patient 1. Sagittal T1-weighted image shows an iso- to hypointense mass in the cervical cord 
(A). The lesion is better demarcated on the sagittal T2-weighted sequence (B). An intense peripheral enhancement is shown 
on the contrast enhanced axial and sagittal T1-weighted images (C-F). Observe the exophytic component of the lesion in its 

































Fig. 2 – Histological images from patient 1, showing a 
hypercellular proliferation composed of round-to-oval 
medium-sized nuclei, with foci of necrosis (A. hematoxylin 
and eosin stains, 200 ×), with strong and diffuse GFAP 
expression (B, 200 ×). Absence of IDH1 R132H mutation (C, 
200 ×, with positive control in the inset), absence of ATRX 
expression with positive internal control, consistent with 










of aggressive multimodality treatment [2] . The highest inci-
dence is between the second and third decade of life [2] , and
the most common location is the cervical and thoracic spinal
cord. Less commonly, it can occur in the conus medullaris [3] .
Due to its rarity, spinal cord GB might be misdiagnosed ra-
diologically with infectious and inflammatory conditions, or
with less malignant and more common types of spinal cord
tumors. 
We report 3 cases of spinal cord GB, analyze the imag-
ing features, and discuss differential diagnoses of this rare
disease. 
Case 1 
A 34-year-old woman with a history of neurofibromatosis
type 1 (NF1), presented to the emergency department with
motor weakness of the right arm and sensory disturbances
of the lower limbs that started 4 days before admission. The
patient had no fever or systemic symptoms, and no previous
history of cancer or trauma. On neurological examination, the
patient showed paraparesis and hypoesthesia of the upper
extremities and general hyper-reflexia of the lower limbs. A
cervical spine MRI showed an extensive intraspinal - intradu-
ral infiltrative expansile lesion with an exophytic component,
which involved nearly the entire cervical spinal cord, and
extended cranially to the lower part of the medulla oblongata
including the area postrema ( Fig. 1 ). The lesion showed a
homogeneous peripheral and eccentric enhancement of
both the intramedullary and exophytic components of the
lesion at its proximal segment ( Fig. 1 ). Brain MRI showed
only bilateral subcutaneous epicranial lesions in the occipital
regions, compatible with neurofibromas, and a left parotid
lesion suggestive of a plexiform neurofibroma. Oligoclonal
bands in CSF and serum antibodies to aquaporin-4 (AQP4-Ab)
were negative. A spinal cord biopsy was performed, and a
highly cellular lesion composed of medium-sized, oval nuclei
with granular chromatin and eosinophilic cytoplasm was 
found on histological analysis. Two mitoses were identified
in the whole material, with frequent foci of necrosis and
endothelial hyperplasia. The neoplastic cells expressed glial
fibrillary acidic protein (GFAP), with loss of ATRX expression.
No isocitrate dehydrogenase (IDH), BRAF nor H3 K27M muta-
tions were found and no p53 overexpression was seen. The
proliferation index (measured by Ki67) reached 7%. These
findings were consistent with a grade IV, IDH-wild type GB
(WHO 2016) ( Fig. 2 ). Due to the location and histopathology
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Fig. 3 – Spinal cord MRI from patient 2. Sagittal T1-weighted image shows an iso- to hypointense mass in the conus 
medullaris (A). The lesion is better demarcated on the sagittal T2-weighted sequence (B). An intense peripheral 
enhancement delimiting a central area of necrosis associated with an eccentric enhancing nodule (arrow in C) is shown on 



































Fig. 4 – Histological images from patient 2 (hematoxylin 
and eosin stains, 200 ×). The sample shows hypercellular 
proliferation composed of oval medium-sized nuclei, with 
















of the tumor, and the rapid clinical deterioration, it was
decided not to perform any treatment. The patient developed
hydrocephalus and passed away 2 months after admission,
most likely to rapid disease progression. 
Case 2 
A 64-year-old man without any past medical history presented
to the emergency department after a 3-week history of mo-
tor weakness of the lower extremities with associated sensory
disturbances. Neurological examination showed paraparesis
and decreased sensation in the anterior region of both thighs
and in the genital and the perianal areas. There were no neu-
rologic abnormalities of the upper limbs and cranial nerves
and no sphincter dysfunction. A lumbar spine MRI revealed
an ovoid, intramedullary, expansile lesion involving the conus
medullaris with homogeneous hyperintense signal inten-
sity on T2-weighted images. After injection of contrast, the le-
sion demonstrated an irregular, thick peripheral enhance-
ment, delineating a central area of necrosis associated with
an eccentric enhancing nodule ( Fig. 3 ). These imaging features
were consistent with a spinal cord tumor, although an infec-
tious lesion was also considered. Serological testing for dif-
ferent infectious diseases including Toxoplasma gondii was all
negative. The patient was surgically treated with partial re-
section of the lesion. Histologically, a moderately cellular le-
sion composed of medium-sized, oval, hyperchromatic nuclei
with scant cytoplasm was identified, with a prominent myx-
oid background ( Fig. 4 ). Mitotic activity reached 5 mitoses/10
high power fields, with necrosis and vascular proliferation.
The neoplastic cells expressed GFAP and preserved ATRX ex-
pression. No IDH mutations, epidermal growth factor recep-
tor (EGFR) amplification nor BRAF translocation were found.
P53 expression reached 40%. The proliferation index (mea-
sured by Ki67) reached 30%. These findings were consistent
with a grade IV, IDH-wild type GB (WHO 2016). The patients
started treatment with radiotherapy and chemotherapy, but
recurrent disease was demonstrated 13 months later, and he
passed away 20 months after his initial diagnosis. Case 3 
A 47-year-old patient with a history of hyperuricemia and ar-
terial hypertension presented to the hospital with 18 months
history of progressive spinal cord symptoms with paresthe-
sia in the lower right extremity starting in the foot and as-
cending to the leg, accompanied by episodes of intense pain,
loss of thermic sensitivity, and numbness of left arm. A cer-
vicothoracic spine MRI was performed in another institution
that showed 2 tumefactive intramedullary lesions involving
the cervical and thoracic segments. A diagnosis of tumefac-
tive inflammatory lesions was initially suggested and the pa-
tient was treated with corticosteroids, without clinical im-
provement. Oligoclonal bands in CSF and serum antibodies
to aquaporin-4 (AQP4-Ab) and myelin oligodendrocyte glyco-
protein (MOG) were negative. The patient clinically progressed
over the next 4 weeks, developing motor weakness of his left
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Fig. 5. – Spinal cord MRI from patient 3. Sagittal STIR image 
shows multifocal lesion that affects the cervical (C5-C7) and 
dorsal (D3-D5) spinal cord segments (A). Contrast-enhanced 
sagittal and axial T1-weighted images (B-E) demonstrates 
peripheral enhancement and a small necrotic center 
(arrows). 
Fig. 6 – Histological images from patient 3 (hematoxylin 
and eosin stains, 200 ×). Observe the hypercellular 
proliferation composed of large and medium-sized nuclei, 

































































arm, and came to our institution for a more extensive diag-
nostic work-up. A new cervicothoracic spine MRI revealed 2
fusiform expanding lesions involving the C5-C7 and T3-T5
spinal cord segments, with contrast-uptake delineating cen-
tral areas of necrosis ( Fig. 5 ). A spinal cord biopsy was per-
formed on the cervical cord lesion, which showed a highly
cellular tumor, composed of large and irregular nuclei, with
frequent bizarre and multinucleated cells, and a high mi-
totic index (reaching 13/10 high power fields). Frequent im-
ages of vascular proliferation and necrosis were found ( Fig. 6 ).
The neoplastic cells expressed GFAP. No p53 overexpression,
EGFR amplification nor IDH and BRAF mutations were present.
The proliferation index (measured by Ki67) reached 65%.These findings were consistent with a grade IV, IDH-wild type
GB (WHO 2016). The patient was treated with radiotherapy
and chemotherapy but rapidly progressed clinically and ra-
diologically and passed away 10 months after first hospital
admission. 
Discussion 
Glioblastoma is the most frequent malignant tumor of the
CNS, and constitutes 12%-15% of all intracranial neoplasms
[4] , but it is a rare entity in the spinal cord, with only less than
200 cases reported in the literature [1] . Spinal cord GB has a
predilection to develop from the cervical cord segment and
has a tendency to develop at a younger age compared to those
primarily involving the brain [5] . 
Histopathologically, spinal cord and brain GB are identical.
However, there is no molecular marker specific for spinal cord
GB and markers such as IDH-1 and O6-methylguanine-DNA
methyltransferase promoter methylation only have prognos-
tic significance for supratentorial GBs [6] . 
Its location at the cervical spinal cords segment is more fre-
quent and clinical symptoms depend on the degree of spinal
cord damage [7] . These tumors frequently show contiguous
dissemination, and through cerebrospinal fluid also dissemi-
nate to distant sites, which significantly reduce survival [8] . 
Spinal cord MRI is considered the gold standard imaging
modality to diagnose spinal intramedullary tumors, although
differentiation of primary spinal cord GB from other spinal
cord diseases, such as infectious and inflammatory disorders,
or other intramedullary tumors, is challenging, since primary
spinal cord GBs show MRI features that are similar to these
conditions (intramedullary longitudinally extensive lesions
with patchy heterogeneous enhancement and intralesional
cysts or necrosis). Therefore, a definitive diagnosis requires
tissue biopsy and histopathological evaluation. The majority
of primary spinal cord GBs appear as infiltrative expansive
masses with iso or low signal on T1-weighted, and high signal
on T2-weighted images, and heterogeneous enhancement on
contrast-enhanced T1-weighted images [1] . Nonconventional
MRI sequences could provide additional useful features,
such decrease in fractional anisotropy on diffusion tensor
images that correlates with the severity of infiltration and
destruction of spinal nerve tissue [9] and increase in relative
blood volume ( > 1.8) on dynamic susceptibility contrast MRI
perfusion caused by the angiogenesis that characterized
these tumors [9] . 
In the first patient, the lesion had an exophytic exten-
sion, defined as the growth of tumor beyond the pia mater
and into the subarachnoid space, which has been previously
described in spinal cord GB [10] . In this case, the initial dif-
ferential diagnosis included, in addition to GB, pilocytic as-
trocytoma, ependymoma, and neuromyelitis optica spectrum
disorder (NMOSD). Pilocytic astrocytoma is the most common
intramedullary tumor in patients with NF1 [11] , and mainly
involves the cervical segment arising eccentrically within the
cord. Additional imaging features are a cystic mass with a
mural nodule showing a diffuse nonhomogeneous contrast
enhancement [12] . Ependymomas have been also described































































as associated with NF-1, but we could not find in the medi-
cal literature and association between NF-1 and GB. NMOSD
was considered in the differential diagnosis, as the lesion ex-
tended to the area postrema in the lower part of the brainstem,
an MRI feature initially considered to be specific to NMOSD,
but later seen in other conditions associated with longitudi-
nally extensive cervical cord lesions [13] . Also, the presence
of the exophytic component suggested this diagnosis, as lep-
tomeningeal enhancement has been described in this condi-
tion [14] However, this diagnosis was excluded as AQP4 anti-
bodies were not detected and there was no additional clinical
involvement beside the spinal cord, which is a requirement
to establish this diagnosis according to the 2015 NMOSD diag-
nostic criteria [15] . 
The second case was a GB located in the conus medullaris,
which is a very rare location for this tumor. A retrospective
study that collected 128 cases from 1938 to 2015, showed that
42.2% of spinal cord GBs were located in the thoracic spine,
29.7% in the cervical spine, while those located in the conus
level only accounted for 14% of cases [3 ,4] . In fact, we did not
even consider a GB in the initial differential diagnosis, while
our first suggestion was of a myxopapillary astrocytoma, a
slow-growing variant of spinal cord ependymoma, due to its
location in the conus medullaris. However, myxopapillary as-
trocytomas, which mainly affect young adults, appear as cir-
cumscribed enhancing masses with a tendency to show cystic
and hemorrhagic changes [16] . Another diagnosis that could
be considered in this case is a spinal cord embryonal tumor, a
rare and aggressive tumor, with a poor prognosis [17] , which
similar imaging features to GB (heterogeneous enhancement
and necrosis), although tumor tend to manifest in young chil-
dren [16] . Finally, the presence of an eccentric enhancing nod-
ule also suggested the diagnosis of toxoplasmosis, as the ec-
centric target sign has been considered pathognomonic for
cerebral toxoplasmosis [18] . However, toxoplasmic myelitis, a
rare condition seen in immunocompromised hosts, was ex-
cluded in our patient through appropriated laboratory testing.
In the third case, the initial diagnosis was a tumefactive
inflammatory lesion, as presence of longitudinally extensive
lesions with at least 2 noncontiguous lesions has been fre-
quently described in MOG-IgG myelitis and rarely in AQP4-
IgG myelitis [19] . However, these conditions were excluded as
serum analysis of these antibodies was negative. Moreover,
the rapid clinical and MRI progression suggested the diagno-
sis of an aggressive tumor, and spinal cord biopsy finally es-
tablished the diagnosis of GB. 
Conclusion 
Spinal cord GBs are extremely rare entity and are generally
associated with a dismal outcome. Although MRI plays a vi-
tal role in the diagnosis of spinal cord tumors, imaging fea-
tures are not specific and commonly unable to differentiate
glioblastoma from other less aggressive and more common
spinal cord tumors, and from infectious and inflammatory
conditions. However, tumefactive spinal cord lesions with en-
hancement and necrosis in a young adult patient should raise
the diagnosis of GB and a prompt biopsy should be performedto confirm this diagnosis, after reasonable exclusion of infec-
tious and inflammatory conditions through appropriate labo-
ratory tests. 
Patients Consent Statement 
Written informed consent could not be obtained from the pa-
tients as they all were exitus few months after diagnosis. All
the images included in this Case report are entirely unidentifi-
able and there are no personal details on individuals reported
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